S_mmary Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every Intrapleural IL-2 levels were high (>20 000 IU ml-') at levels E and F, while serum levels in most patients were not or barely detectable (<3-30 IU ml-'). Intrapleural IL-2 levels were up to 6000-fold higher than systemic levels. Intrapleural tumour necrosis factor alpha (TNF-a) levels varied greatly and did not correlate with IL-2 dosage. Intrapleural mononuclear cells (MNCs) displayed IL-2-induced lymphokine-activated killer (LAK) activity in all patients. Two patients were not evaluable for response owing to catheter-related problems which precluded the delivery of IL-2. Partial response (PR) occurred in 4 of 21 evaluable patients (19%; 95% confidence interval 5-42%) with a median time to progression of 12 months (range 5-37). Stable disease (SD) occurred in seven patients with a median time to progression of 5 months (range 2-7). There were no complete responses (CRs). The median overall survival was 15.6 months (range 3.0-43). No relationship between the dose of IL-2 and response rate was observed. We conclude that IL-2 given intrapleurally is accompanied with acceptable toxicity and has anti-tumour activity against mesothelioma. In view of the refractory nature of the disease IL-2 may be a treatment option for mesothelioma. A formal phase II study is warranted. Based on the observed toxicity, the lack of dose-response relationship and the immunomodulatory effects seen at relatively low-dose IL-2, the recommended dose for a phase II study is 3 x I06IU day-' using the present treatment schedule.
Untreated patients with pleural mesothelioma have a median survival of 9 months and may survive just as long as treated patients (Hillerdal, 1983; Law et al., 1984) . Current treatment methods do not appear to improve survival (Alberts et al., 1988) . Therefore, new treatment modalities should be investigated.
In intraperitoneal tumour models it has been demonstrated that intracavitary administration of interleukin 2 (IL-2) can induce very high numbers of lymphokine-activated killer cells (LAKs) in the peritoneal exudate Eggermont 1989) . Consequently, intrapleural administration of IL-2 for the treatment of pleural mesothelioma appears to be a reasonable therapeutic approach, particularly since mesothelioma tends to be confined to the pleural cavity for most of the course of the disease. Yasumoto et al. (1987) reported the complete clearance of malignant cells after intrapleural instillations of IL-2 in patients with pleurisy due to lung cancer. Astoul et al. (1993) reported objective responses in mesothelioma patients treated with continuous intrapleural IL-2 instillation.
Based on these observations, we performed phase I-II study with intrapleural IL-2 in patients with pleural mesothelioma stage I-IIA, classified according to the Butchart staging system (Butchart et al., 1976) .
Patients and methods

Patients
Staging and diagnosis of mesothelioma was based on computerised tomographic (CT) scan of the chest, thoracoscopic findings and histological examination of biopsy samples.
All biopsies were reviewed by our institution's pathologist. The staining techniques used included haematoxylin and eosin, special stains for reticulin and mucins (such as mucicarmine, periodic acid-Schiff after diastase and the alcian blue stain with and without prior digestion with hyaluronidase) and the immunohistochemistry stain for CEA, keratin, CAM-5.2 and an epithelial membrane antigen MOC-31.
According to Butchart's staging system (Butchart et al., 1976) (Tables I and H) . Two patients were inevaluable for toxicity and response owing to catheterrelated problems which prevented the delivery of any IL-2. At least one treatment cycle of 14 days was recived by five patients at 3 x 104 IU day-', two patients at 3 x 105 IU day-, three patients at 3 x I0'IU day-', three patients at 6 x 10 IU day-', three patients at 18 x 10' IU day-' and one patient at 36 x 10 IU day-'. Five patients were starte at the highest dose level but only one patient was able to receive one cycle. The other four patients were unable to complete one treatment cycle because of catheter-related infections which required catheter removal before the completion of the first cycle. After five patient entries at this dose level the study was stopped. Hence, this dose was not tolerated by four of the five patients (Table 1) .
In general IL-2-mediated toxicity was mild to moderate, except at the highest dose level. At this level, in addition to the catheter-related infections, fever and flu-hlke symptoms were dose lmiting. The systemic side-effects such as fever and skin toxicity corresponded with serum IL-2 levels, which reached 301Uml-' in group F. All patients rLived their Clinical signs of empyema were noted in five of the seven patients with a Port-a-cath infection. These five required removal of the Port-a-cath system in combination with drainage by thoracotomy. As can be seen in Table I a variety of micro-organisms were cultured from pleural samples and removed Port-a-cath systems of these patients which suggests a secondary bacterial infection in necrotic tissue.
Patients received from less than one up to six complete treatment cycles. There were no complete responses. Partial response occurred in 4 of 21 evaluable patients (19%; 95% confidence intervals 5-42%) with a median time to progression of 12 months (range 5-37). Stable disease occurred in seven patients, the median time to progression was 5 months (range 2-7). Six patients had progressive disease. The median overall survival was 15.6 months (range 3.0-43). Responses occurred at different dose levels, therefore no dose-response relationship can be establshed (Table H) . Figure 1 shows a representative example of a tumour response.
Tree of the four PRs was a long-lasting response underwent thoracotomy. In patients 10 and 8, an infected Port-acath with concomitant empyema was noted after one and four cycles, respectively (Table II) Immwwmonitoring After intrapleural administration of IL-2 a mild increase of CD3-56+, CD3+56+ and CD3-16+ lymphocytes was observed in pleural effusion as well as in peripheral blood. All other T-lymphocyte subsets remained at normal levels.
At dose levels A-D cytotoxiity assays showed a significant induction of LAK activity by pleural effusionderived MNCs but not by peripheral blood MNCs. At dose levels E and F, LAK activity was induced in MNCs from both sites. Of note, no differences in LAK activity werseen between responders and non-responders.
Determination of cytokine levels Intrapleural as well as serum IL-2 levels were determined.
Intrapleural levels were very high and correlated with the administered dose of IL-2. Intrapleural levels varied from 6-llOIUml-' in group A to as high as 66000-1920001U ml-' in group F. Serum IL-2 levels became measurable only in groups E and F and varied in the eight patients treated at those levels from < 3 IU ml' to 30 IU ml '. Itraplural LL-2 levels were <6000 times higher than serum lves.
-Intrapleural TNF-1 levels varied from 50-125pgmlI in group A to 235-405 pg ml-' in group F. However, no cear relationship between TNF-c and IL-2 lewls was observed as TNF-a levels in groups B-E varied from 292-1141 pg ml-'.
In this phase I-II study on the toxicity and efficacy of intrapeural administraton of IL-2 in patients with pleural mesothelioma we observed anti-tumour activity with acceptable toxcity. The response rate of 19% in 21 patients is of interest as mesothelioma is known to be refractory to treatment.
The basis of this study was the observation of a dose-response relationship in experimental tumour models (Etfinghausen et al., 1986; Rosenberg et al., 1987 Rosenberg et al., , 1989 Fermont et al., 1988) . Systemic high-dose EL-2 therapy is associted with severe toxicity, which may prohibit applation of doses with optimal anti-tumour effects (Herberman, 1989 levels of IL-2 can be delivered without severe systemic adverse effects. We have demonstrated that high intrapleural levels of IL-2 are associated with mild to moderate toxicity, except in those patints treated at the highest dose level F with 36x l0'IUday '. All patients in groups A-E were treated on an outpatient basis. Intrapleural administration of various biological response modlifiers may have significant anti-tumour effects against intrapleural malignant disease. Uchida et al. (1984) reported that intrapleural instillation with the biological response modifier OK-432 significantly increased autologous tumour killing by tumour-associated large granular lymphocytes. The intrapleural instillation of natural a-interferon was reported to be effective against malignant pleural effusions by Rosso et al. (1988) . Recently, Markowitz et al. (1992) reported on the efficacy of intracavity administration of a-interferon. Boutin et al. (1991) reported four CRs and two PRs after weekly intrapleural administration of y-interferon in 22 patients with mesothelioma, also underlining the therapeutic potential of locoregional cytokine therapy.
Anti-tumour effects after intrapleural administration of TNF--a have been reported by Karck et al. (1990) . Int- rapleural administration <200 fg m-2 weekly in seven patients with malignant pleural effusion led to complete disappearance of tumour in three patients without sideeffects. The (Murphy et al., 1988; Jablons et al., 1990; Klempner et al., 1990) . High-dose IL-2 increased the risk of bacteraemia significantly, which led to a reduction of catheter indwelling time (Richards et al., 1991) . These facts may explain the high incidence of catheter-related infections in our patients, particularly in group F, and after repeated administration of IL-2 at the lower doses. It remains uncertain if and to what extent these infections have played a role in the induction of an anti-tumour response, as three of the four responders developed an empyema, but two of the five patients with an empyema had no response. In addition, IL-2 by itself induced high intrapleural levels of TNF-a in the majority of the patients treated.
We conclude that intrapleural administration of cytokines should be explored further as a new mode of treatment for pleural mesothelioma. IL-2 given intrapleurally appears to have anti-tumour activity against mesothelioma. We are aware of the difficulty in recommending a daily dose of IL-2 because of the small numbers of patients in each group and the frequent occurrence of empyema, but given the facts that (1) no correlation was found by us and by others between IL-2 dose and anti-tumour response, (2) low intrapleural IL-2 doses are sufficient to induce LAK activity by MNCs which can kill NK cell-resistant human mesothelioma cells and (3) mild toxicity was seen below 6 x 106 IU of IL-2 we suggest a daily dose of 3 x 106 IU of IL-2 for a phase II study.
